Synonyms
Funguard; Micafungin sodium salt; Micafungin Na; FK-463; IS1UP79R56; Fungard
Molecular Formula
C56H70N9NaO23S
Smiles
CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC(=C(C=C7)O)OS(=O)(=O)[O-])O)O)[C@@H](CC(=O)N)O)C)O)O)O.[Na+]
Appearance
Light-sensitive, hygroscopic white powder
Relative Density
1.62±0.1 (Predicted)
General Description
Micafungin sodium is a semi-synthetic lipopeptide antifungal belonging to the echinocandin class, containing a cyclic hexapeptide core with a fatty acid side chain. Its structure includes a threonine and a 4-hydroxy-3-methoxybenzoic acid group. The sodium salt provides water solubility.
Mechanism of Action
Micafungin non-competitively inhibits β-1,3-D-glucan synthase, an enzyme essential for the synthesis of β-glucan, a critical component of the fungal cell wall. The inhibition disrupts cell wall integrity, causing osmotic instability and cell lysis. The drug is fungicidal against Candida species and fungistatic against Aspergillus species. It has a unique binding site on the synthase enzyme, distinct from that of other echinocandins.
Application
Micafungin is indicated for the treatment of candidemia, acute disseminated candidiasis, and other Candida infections (peritonitis, abscesses), as well as for the prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. It is also used for the treatment of esophageal candidiasis.
Micafungin killed Candida albicans SC5314 in a metabolic activity-dependent manner and induced cell wall remodeling, exposing β-glucan and chitin on the surface. At higher doses, it caused budding yeast lysis. Pre-incubation with micafungin before macrophage exposure enhanced TNF-α, IL-17A, and IL-10 secretion. Micafungin potentiates the immune response by unmasking β-glucans, improving macrophage activation beyond its direct antifungal effect.
Fig. 1 Cell survival, metabolic activity, and level of toxicity in Candida albicans upon micafungin treatment is a function of the nutritional status of the medium. (Guirao-Abad JP, et al., 2018)
References
- Guirao-Abad JP, et al. Micafungin Enhances the Human Macrophage Response to Candida albicans through β-Glucan Exposure. Antimicrob Agents Chemother. 2018;62(5):e02161-17.
In a randomized trial of 56 preterm neonates with invasive fungal infection, micafungin (8 mg/kg/day) achieved higher complete cure rates than amphotericin B (1 mg/kg/day): 64.3% vs 35.7%, P=0.030. Micafungin was effective against both Candida albicans and non‑albicans, and reduced duration of respiratory/circulatory support. Mild hypomagnesemia occurred with micafungin, while amphotericin B increased blood urea nitrogen. Micafungin is effective and well tolerated in preterm neonates.
Fig. 2 Frequency of the cured patients according to the type of fungal species in both studied groups. (Ibrahim MJA, et al., 2025)
References
- Ibrahim MJA, et al. Micafungin versus Amphotericin B in treatment of invasive fungal infection in preterm neonates: a randomized control trial. Ital J Pediatr. 2025;51(1):61.
Does Micafungin Sodium require refrigerated storage as an echinocandin antifungal?
Yes, it must be stored at 2-8°C. At room temperature, degradation via hydrolysis of the cyclic hexapeptide and oxidation occurs.
Is Micafungin Sodium sensitive to light and moisture during handling?
Yes, it is photosensitive and hygroscopic. Store in light-resistant, moisture-proof containers under refrigeration. Handle under subdued light.
What is the stability of Micafungin Sodium after reconstitution for intravenous infusion?
Reconstituted solutions are stable for up to 24 hours under refrigeration and 6 hours at room temperature when protected from light.
How is the impurity micafungin M-5 (a degradation product) monitored?
This degradation product is specifically quantified using a stability-indicating HPLC method, ensuring it remains within ICH limits.